Regulatory FDA, after turbulent year, leaves drugmakers guessing on its direction pharminent April 1, 2026
Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma pharminent April 1, 2026
Clinical Data ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose pharminent April 1, 2026
Clinical Data ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit pharminent April 1, 2026
Regulatory S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD pharminent March 31, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
Clinical Data PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease pharminent March 31, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
Other S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD pharminent March 31, 2026
Other Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 pharminent March 31, 2026
Other Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Clinical Data Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout pharminent March 30, 2026
Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug pharminent March 30, 2026
Clinical Data Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline pharminent March 30, 2026
Market Access The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments pharminent March 30, 2026
Other S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC pharminent March 27, 2026
